Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Baird Downgrades ABM Indus to Neutral, Lowers Price Target to $51

Baird Downgrades ABM Indus to Neutral, Lowers Price Target to $51

Baird analyst Andrew Wittmann downgrades ABM Indus (NYSE:ABM) from Outperform to Neutral and lowers the price target from $52 to $51.

byBenzinga Newsdesk

March 9, 2023

1 minute read

Baird analyst Andrew Wittmann downgrades ABM Indus (NYSE:ABM) from Outperform to Neutral and lowers the price target from $52 to $51.

Analyst Ratings

5 Analysts Have This to Say About Relay Therapeutics

By Benzinga Insights

September 30, 1:11 PM

Relay Therapeutics (NASDAQ:RLAY) has observed the following analyst ratings within the last quarter:

RLAY

Why Cerevel Therapeutics Holdings Shares Are Nosediving

By Henry Khederian

November 8, 2:10 PM

Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) shares are trading lower by 6.42% to $25.37 during Tuesday's session after the company reported worse-than-expected third-quarter EPS results and filed for a mixed-securities shelf offering of up to $900 million.

CERE